Lymphoma, Non-Hodgkins
6 clinical trials · Condition
◉ Watch Lymphoma, Non-Hodgkins
| Record | Firm | Date |
|---|---|---|
| T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma (NCT04160195) | National Cancer Institute (NCI) | 2019-12-20 |
| T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies (NCT02659943) | National Cancer Institute (NCI) | 2016-01-21 |
| Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab (NCT01119794) | Brown University | 2010-07-01 |
| Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors (NCT00713882) | Weill Medical College of Cornell University | 2008-04-01 |
Track Lymphoma, Non-Hodgkins automatically
Every clearance here is in the API, with alerts when new ones post.